The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease

Sebastian Paus*, Anne Grünewald, Christine Klein, Michael Knapp, Alexander Zimprich, Bernd Janetzky, Jens C. Möller, Thomas Klockgether, Ullrich Wüllner

*Corresponding author for this work
17 Citations (Scopus)

Abstract

Previous studies have demonstrated that the TaqIA polymorphism of the D2 dopamine receptor gene (DRD2) is associated with response to dopaminergic and antidopaminergic treatment in Parkinson's disease (PD) and schizophrenia, respectively. We tested whether the TaqIA genotype in PD is responsible for demand of dopaminergic medication, measured in total dopaminergic load per year of disease, in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Regression analysis yielded no significant differences between the TaqIA genotypes. We conclude that the DRD2 TaqIA polymorphism alone has no pivotal role for interindividual variability of dopaminergic requirement in PD. We propose a practicable system of measuring dopaminergic treatment for future pharmacogenetic studies in PD.

Original languageEnglish
JournalMovement Disorders
Volume23
Issue number4
Pages (from-to)599-602
Number of pages4
ISSN0885-3185
DOIs
Publication statusPublished - 15.03.2008

Fingerprint

Dive into the research topics of 'The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease'. Together they form a unique fingerprint.

Cite this